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Glioblastoma Multiforme (GBM) is an aggressive cancer that originates from astrocytes 
and spreads to spinal cord and other parts of the brain. Increase in replication of glial 
cells leads to advantageous mutations in the tumor. In 2015 about 15,320 deaths were 
reported due to GBM. Five-year survival is less than 5% making GBM a dreadful cancer. 
Current treatment involves complex invasive surgery, followed by chemotherapy and 
radiation. There is a desperate unmet need for a targeted treatment of GBM with 
minimum damage to the surrounding normal tissue. Combination treatments are 
increasingly being used to target multiple hallmarks of cancer. The goal of this study is to 
develop a combination therapy to treat GBM using Poly (lactic-co-glycolic acid) (PLGA) 
nanoparticles encapsulated with three different drugs namely gefitinib, temozolomide 
(TMZ) and GSK461364 each with a unique target. Nanoparticles facilitate combination of 
multiple drugs for simultaneous delivery to cancer cells in a single nano-sized platform. 
Gefitinib is a Tyrosine Kinase inhibitor, which competes for ATP-binding site of EGFR-
TK. TMZ methylates DNA of tumor cells, resulting in apoptosis. GSK461364 is a Polo-
like Kinase (PLK-1) inhibitor that blocks the G2/M transition in tumor cell cycle. These 
three distinct hydrophobic drugs are tested on U-87 MG (human malignant glioma) and 
MDA-MB-231 (triple negative breast cancer) cell lines. PLGA is attached to Polyethylene 
glycol (PEG), which is conjugated to transferrin receptor (TfR) binding peptide for 
targeting TfR overexpression, common in GBM. PEG is known to increase the circulation 
half-life in vivo and improves colloidal stability of nanoparticles. These transferrin 
peptides bind to TfR (or CD71) and enable the entry of PLGA across Blood Brain Barrier 
(BBB). Results of characterization, in vitro drug release profiles, stability at 37°C and 
4°C, cytotoxicity assay, electron micrographs of nanoparticles containing drugs and 
fluorescent imaging will be presented. 
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